These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29719204)

  • 41. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity.
    Caputo F; Francini S; Brambilla R; Vigna-Taglianti F; Stoppo M; Del Re A; Leggio L; Addolorato G; Zoli G; Bernardi M
    Eur Neuropsychopharmacol; 2011 Jun; 21(6):450-6. PubMed ID: 21276717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Spanagel R; Zieglgänsberger W
    Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of alcohol dependence: recent progress and reduction of consumption.
    Testino G; Leone S; Borro P
    Minerva Med; 2014 Dec; 105(6):447-66. PubMed ID: 25392958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
    Drobes DJ; Anton RF; Thomas SE; Voronin K
    Neuropsychopharmacology; 2003 Apr; 28(4):755-64. PubMed ID: 12655322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An overview of medications for the treatment of alcohol withdrawal and alcohol dependence with an emphasis on the use of older and newer anticonvulsants.
    Ait-Daoud N; Malcolm RJ; Johnson BA
    Addict Behav; 2006 Sep; 31(9):1628-49. PubMed ID: 16472931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
    Leone MA; Vigna-Taglianti F; Avanzi G; Brambilla R; Faggiano F
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006266. PubMed ID: 20166080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?
    Haass-Koffler CL; Akhlaghi F; Swift RM; Leggio L
    J Psychopharmacol; 2017 Jul; 31(7):812-818. PubMed ID: 28093021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Severe opioid withdrawal syndrome after a single dose of nalmefene.
    Donnerstag N; Schneider T; Lüthi A; Taegtmeyer A; Raetz Bravo A; Mehlig A
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1025-6. PubMed ID: 26050241
    [No Abstract]   [Full Text] [Related]  

  • 50. The effectiveness of pharmacological approaches in the treatment of alcohol withdrawal syndrome (AWS): a literature review.
    Cooper E; Vernon J
    J Psychiatr Ment Health Nurs; 2013 Sep; 20(7):601-12. PubMed ID: 22989012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nalmefene and its use in alcohol dependence.
    Gual A; Bruguera P; López-Pelayo H
    Drugs Today (Barc); 2014 May; 50(5):347-55. PubMed ID: 24918835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The recognition and management of protracted alcohol withdrawal may improve and modulate the pharmacological treatment of alcohol use disorder.
    Caputo F; Cibin M; Loche A; De Giorgio R; Zoli G
    J Psychopharmacol; 2020 Nov; 34(11):1171-1175. PubMed ID: 32648800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.
    Petrakis IL; Nich C; Ralevski E
    Schizophr Bull; 2006 Oct; 32(4):644-54. PubMed ID: 16887890
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.
    Köhne S; Hillemacher T; Glahn A; Bach P
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):219-232. PubMed ID: 38606899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drugs for alcohol use disorder.
    Med Lett Drugs Ther; 2021 Dec; 63(1639):193-198. PubMed ID: 35100235
    [No Abstract]   [Full Text] [Related]  

  • 56. Medications for treating alcohol use disorder: A narrative review.
    Kranzler HR; Hartwell EE
    Alcohol Clin Exp Res (Hoboken); 2023 Jul; 47(7):1224-1237. PubMed ID: 37526592
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Severe Alcohol Withdrawal.
    Schmidt KJ; Doshi MR; Holzhausen JM; Natavio A; Cadiz M; Winegardner JE
    Ann Pharmacother; 2016 May; 50(5):389-401. PubMed ID: 26861990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
    Di Nicola M; De Filippis S; Martinotti G; De Risio L; Pettorruso M; De Persis S; Maremmani AGI; Maremmani I; di Giannantonio M; Janiri L
    Adv Ther; 2017 Jul; 34(7):1636-1649. PubMed ID: 28540656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recommended drug treatment strategies for the alcoholic patient.
    Schaffer A; Naranjo CA
    Drugs; 1998 Oct; 56(4):571-85. PubMed ID: 9806104
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Meta-analysis of pharmacological therapy with acamprosate, naltrexone, and disulfiram--a systematic review].
    Petrov I; Krogh J; Nordentoft M
    Ugeskr Laeger; 2011 Nov; 173(48):3103-9. PubMed ID: 22118653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.